Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101593 | 0.84 | KDM4E (0.44) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL21101598 | 0.81 | LSS (0.37) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL18909625 | 0.80 | KDM4E (0.41) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14575794 | 0.78 | KDM4E (0.46) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14575792 | 0.78 | KDM4E (0.46) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL18909608 | 0.78 | KDM4E (0.42) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL14576545 | 0.76 | KDM4E (0.45) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL14576547 | 0.76 | KDM4E (0.45) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL30719696 | 0.76 | KDM4E (0.41) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL15135714 | 0.76 | KDM4E (0.41) | KDM4EHTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | KDM4E 255/4885HTR2A 3926/4885HTR2C 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.